BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261005T080000
DTEND;TZID=America/New_York:20261005T093000
DTSTAMP:20260902T231038
CREATED:20260803T151752Z
LAST-MODIFIED:20260902T180607Z
UID:3241-1791187200-1791192600@lifescievents.com
SUMMARY:Compugen Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update
DESCRIPTION:Join Compugen for a virtual key opinion leader (KOL) event featuring Oladapo Yeku\, MD\, PhD\, FACP (Harvard Medical School\, Massachusetts General Hospital)\, who will join company management to discuss the evolving treatment landscape in ovarian cancer. \nDr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial of COM701\, a potential first-in-class anti-PVRIG antibody\, evaluating safety and efficacy in the maintenance treatment of relapsed platinum sensitive ovarian cancer (PSOC)\, with median progression-free survival data from the interim analysis expected by Q1 2027. \nCompugen’s Research and Discovery team will also provide an update on expanded capabilities of Unigen™\, its AI-based target discovery platform\, which enables the discovery of novel cancer immunotherapy drug targets and the continuous development of first-in-class drugs. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/tp28kry/.
URL:https://lifescievents.com/event/tp28kry/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Events-Banners_2-9.png
END:VEVENT
END:VCALENDAR